Abstract
Severe COVID-19 infection is characterized by intense inflammation and thrombogenesis, related to the elevation of markers such as C-reactive protein, IL-6, D-dimer and ferritin. For these cases, there is a potential benefit of anticoagulant therapies with Heparin and immunomodulatory therapies with Tocilizumab in terms of patient prognosis. Thus, in view of the wide applicability of this…